Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology drug candidates. The company leverages its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), to identify and develop targeted cancer therapies. Its lead drug candidates include ACR-368 and ACR-2316, which are being advanced through preclinical and clinical development for the treatment of various cancers.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115123 | EDGAR | 96K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046056 | EDGAR | 110K words |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037618 | EDGAR | 105K words |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010331 | EDGAR | 108K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-346819 | EDGAR | 22K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280215 | EDGAR | 24K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108054 | EDGAR | 24K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071427 | EDGAR | 22K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125929 | EDGAR | 24K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095760 | EDGAR | 23K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059084 | EDGAR | 20K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061553 | EDGAR | 64K words |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041593 | EDGAR | 63K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019157 | EDGAR | 61K words |
| 2022-12-15 | 2022-09-30 | 0000950170-22-026622 | EDGAR | 68K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-346859 | EDGAR | 2K words |
| 2026-03-19 | 0001193125-26-115139 | EDGAR | 3K words |
| 2026-03-02 | 0001193125-26-085516 | EDGAR | 1K words |
| 2026-02-27 | 0001193125-26-079500 | EDGAR | 2K words |
| 2026-01-08 | 0001193125-26-007077 | EDGAR | 4K words |
| 2026-01-08 | 0001193125-26-007007 | EDGAR | 2K words |
| 2025-11-13 | 0001193125-25-280172 | EDGAR | 2K words |
| 2025-09-05 | 0001193125-25-197250 | EDGAR | 5K words |
| 2025-08-13 | 0001193125-25-179834 | EDGAR | 2K words |
| 2025-06-13 | 0000950170-25-086246 | EDGAR | 1K words |
64 total filings indexed. 39 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001781174 |
| Ticker | ACRV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.acrivon.com |
| Listed | 2022-11-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ACRV (~200 tokens, structured JSON with cryptographic provenance)